Stem definition | Drug id | CAS RN |
---|---|---|
5227 | 1025504-45-3 |
None
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 1.31 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.71 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 18 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 11, 2017 | FDA | NEUROCRINE BIOSCIENCES INC | |
March 28, 2022 | PMDA | Mitsubishi Tanabe Pharma Corporation |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Tardive dyskinesia | 847.77 | 38.22 | 187 | 5107 | 7844 | 56278929 |
Somnolence | 467.95 | 38.22 | 250 | 5044 | 163163 | 56123610 |
Drooling | 382.67 | 38.22 | 84 | 5210 | 3410 | 56283363 |
Tremor | 281.67 | 38.22 | 162 | 5132 | 120927 | 56165846 |
Parkinsonism | 276.18 | 38.22 | 79 | 5215 | 9467 | 56277306 |
Sedation | 222.17 | 38.22 | 93 | 5201 | 34761 | 56252012 |
Dyskinesia | 186.55 | 38.22 | 78 | 5216 | 29030 | 56257743 |
Hospitalisation | 139.24 | 38.22 | 87 | 5207 | 74913 | 56211860 |
Death | 110.00 | 38.22 | 147 | 5147 | 341279 | 55945494 |
Therapeutic product effect decreased | 92.94 | 38.22 | 96 | 5198 | 169356 | 56117417 |
Balance disorder | 92.27 | 38.22 | 68 | 5226 | 76452 | 56210321 |
Adverse drug reaction | 90.27 | 38.22 | 63 | 5231 | 65069 | 56221704 |
Akathisia | 86.41 | 38.22 | 32 | 5262 | 8620 | 56278153 |
Restlessness | 84.85 | 38.22 | 44 | 5250 | 26542 | 56260231 |
Therapeutic product effect incomplete | 84.68 | 38.22 | 74 | 5220 | 105957 | 56180816 |
Drug ineffective | 83.55 | 38.22 | 230 | 5064 | 918759 | 55368014 |
Fall | 61.93 | 38.22 | 116 | 5178 | 357394 | 55929379 |
Urticaria | 58.57 | 38.22 | 70 | 5224 | 144606 | 56142167 |
Anxiety | 54.16 | 38.22 | 78 | 5216 | 193094 | 56093679 |
Feeling abnormal | 53.01 | 38.22 | 64 | 5230 | 133538 | 56153235 |
Dizziness | 51.85 | 38.22 | 111 | 5183 | 376029 | 55910744 |
Nightmare | 48.42 | 38.22 | 26 | 5268 | 16800 | 56269973 |
Bradykinesia | 44.98 | 38.22 | 17 | 5277 | 4837 | 56281936 |
Gait disturbance | 44.37 | 38.22 | 65 | 5229 | 163256 | 56123517 |
Depression | 40.93 | 38.22 | 66 | 5228 | 180051 | 56106722 |
Lethargy | 39.19 | 38.22 | 35 | 5259 | 51406 | 56235367 |
Fatigue | 38.69 | 38.22 | 161 | 5133 | 788391 | 55498382 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drooling | 412.21 | 50.59 | 86 | 2650 | 3009 | 31691599 |
Tardive dyskinesia | 336.11 | 50.59 | 81 | 2655 | 5478 | 31689130 |
Somnolence | 274.08 | 50.59 | 144 | 2592 | 99301 | 31595307 |
Parkinsonism | 171.91 | 50.59 | 51 | 2685 | 7585 | 31687023 |
Tremor | 163.75 | 50.59 | 94 | 2642 | 76326 | 31618282 |
Sedation | 144.00 | 50.59 | 56 | 2680 | 18909 | 31675699 |
Hospitalisation | 100.38 | 50.59 | 59 | 2677 | 49748 | 31644860 |
Drug ineffective | 81.04 | 50.59 | 131 | 2605 | 395442 | 31299166 |
Therapeutic product effect decreased | 78.58 | 50.59 | 43 | 2693 | 31579 | 31663029 |
Dyskinesia | 70.78 | 50.59 | 35 | 2701 | 20875 | 31673733 |
Anxiety | 64.25 | 50.59 | 57 | 2679 | 90976 | 31603632 |
Adverse drug reaction | 61.83 | 50.59 | 34 | 2702 | 25167 | 31669441 |
Death | 59.88 | 50.59 | 109 | 2627 | 360460 | 31334148 |
Fall | 58.85 | 50.59 | 76 | 2660 | 186013 | 31508595 |
Restlessness | 53.16 | 50.59 | 30 | 2706 | 23331 | 31671277 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Tardive dyskinesia | 687.99 | 37.07 | 158 | 5282 | 9771 | 70913233 |
Somnolence | 442.35 | 37.07 | 247 | 5193 | 215359 | 70707645 |
Drooling | 432.89 | 37.07 | 97 | 5343 | 5339 | 70917665 |
Tremor | 293.14 | 37.07 | 169 | 5271 | 155455 | 70767549 |
Parkinsonism | 230.06 | 37.07 | 73 | 5367 | 15252 | 70907752 |
Sedation | 181.98 | 37.07 | 83 | 5357 | 46648 | 70876356 |
Dyskinesia | 153.75 | 37.07 | 71 | 5369 | 41003 | 70882001 |
Death | 146.72 | 37.07 | 187 | 5253 | 509874 | 70413130 |
Hospitalisation | 145.26 | 37.07 | 86 | 5354 | 82482 | 70840522 |
Anxiety | 102.59 | 37.07 | 104 | 5336 | 220226 | 70702778 |
Restlessness | 95.93 | 37.07 | 52 | 5388 | 42076 | 70880928 |
Fall | 85.92 | 37.07 | 135 | 5305 | 443961 | 70479043 |
Balance disorder | 81.21 | 37.07 | 62 | 5378 | 90066 | 70832938 |
Therapeutic product effect decreased | 72.90 | 37.07 | 71 | 5369 | 142947 | 70780057 |
Therapeutic product effect incomplete | 67.71 | 37.07 | 63 | 5377 | 119819 | 70803185 |
Feeling abnormal | 67.61 | 37.07 | 68 | 5372 | 142251 | 70780753 |
Dizziness | 60.86 | 37.07 | 119 | 5321 | 464022 | 70458982 |
Fatigue | 60.44 | 37.07 | 168 | 5272 | 824151 | 70098853 |
Urticaria | 58.24 | 37.07 | 67 | 5373 | 162982 | 70760022 |
Lethargy | 57.50 | 37.07 | 47 | 5393 | 75203 | 70847801 |
Drug ineffective | 56.98 | 37.07 | 179 | 5261 | 939573 | 69983431 |
Akathisia | 54.68 | 37.07 | 24 | 5416 | 12269 | 70910735 |
Adverse drug reaction | 50.89 | 37.07 | 38 | 5402 | 53306 | 70869698 |
Depression | 44.68 | 37.07 | 65 | 5375 | 198909 | 70724095 |
Gait disturbance | 43.80 | 37.07 | 62 | 5378 | 185044 | 70737960 |
Salivary hypersecretion | 41.11 | 37.07 | 20 | 5420 | 12905 | 70910099 |
Insomnia | 38.88 | 37.07 | 64 | 5376 | 217742 | 70705262 |
Bradykinesia | 37.80 | 37.07 | 16 | 5424 | 7486 | 70915518 |
None
Source | Code | Description |
---|---|---|
ATC | N07XX13 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS OTHER NERVOUS SYSTEM DRUGS Other nervous system drugs |
FDA MoA | N0000190855 | Vesicular Monoamine Transporter 2 Inhibitors |
FDA EPC | N0000190856 | Vesicular Monoamine Transporter 2 Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Tardive dyskinesia | indication | 102449007 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.25 | Basic |
pKa2 | 7.56 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 8357697 | Nov. 8, 2027 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10065952 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10844058 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851103 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10851104 | Oct. 28, 2036 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857137 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10857148 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10874648 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10912771 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10952997 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10993941 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11040029 | Oct. 10, 2037 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026939 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11311532 | Sept. 18, 2038 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 11026931 | Aug. 14, 2039 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | 10940141 | Aug. 10, 2040 | TREATMENT OF TARDIVE DYSKINESIA |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
EQ 40MG BASE | INGREZZA | NEUROCRINE | N209241 | April 11, 2017 | RX | CAPSULE | ORAL | April 11, 2022 | NEW CHEMICAL ENTITY |
EQ 60MG BASE | INGREZZA | NEUROCRINE | N209241 | April 23, 2021 | RX | CAPSULE | ORAL | April 11, 2022 | NEW CHEMICAL ENTITY |
EQ 80MG BASE | INGREZZA | NEUROCRINE | N209241 | Oct. 4, 2017 | RX | CAPSULE | ORAL | April 11, 2022 | NEW CHEMICAL ENTITY |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 8.52 | DRUG LABEL | DRUG LABEL | |||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.77 | CHEMBL | |||||
Synaptic vesicular amine transporter | Transporter | INHIBITOR | Ki | 6.73 | IUPHAR |
ID | Source |
---|---|
54K37P50KH | UNII |
1639208-54-0 | SECONDARY_CAS_RN |
C4078701 | UMLSCUI |
CHEMBL2364639 | ChEMBL_ID |
24795069 | PUBCHEM_CID |
DB11915 | DRUGBANK_ID |
D10675 | KEGG_DRUG |
CHEMBL3707248 | ChEMBL_ID |
9744 | INN_ID |
8694 | IUPHAR_LIGAND_ID |
255701 | MMSL |
32624 | MMSL |
d08559 | MMSL |
017167 | NDDF |
017168 | NDDF |
733727001 | SNOMEDCT_US |
763512007 | SNOMEDCT_US |
4036639 | VANDF |
C000603978 | MESH_SUPPLEMENTAL_RECORD_UI |
14580381 | PUBCHEM_CID |
1918219 | RXNORM |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1060 | CAPSULE | 60 mg | ORAL | NDA | 29 sections |
INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1060 | CAPSULE | 60 mg | ORAL | NDA | 29 sections |
INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1080 | CAPSULE | 80 mg | ORAL | NDA | 29 sections |
INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-1080 | CAPSULE | 80 mg | ORAL | NDA | 29 sections |
INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-2040 | CAPSULE | 40 mg | ORAL | NDA | 29 sections |
INGREZZA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70370-2040 | CAPSULE | 40 mg | ORAL | NDA | 29 sections |